Literature DB >> 4016121

The nuclear matrix continues DNA synthesis at in vivo replicational forks.

R A Tubo, H C Smith, R Berezney.   

Abstract

Alkaline cesium chloride gradient analysis of in vivo [3H]bromodeoxyuridine-labeled and in vitro [alpha-32P]dCTP-labeled DNA was used to determine whether in vitro DNA synthesis in regenerating rat liver nuclei and nuclear matrices continued from sites of replication initiated in vivo. At least 70 and 50% of the products of total nuclear and matrix-bound in vitro DNA synthesis, respectively, were continuations of in vivo initiated replicational forks. The relationship of the in vitro DNA synthetic sites in total nuclei versus the nuclear matrix was examined by using [3H]bromodeoxyuridine triphosphate to density label in vitro synthesized DNA in isolated nuclei and [alpha-32P]dCTP to label DNA synthesized in isolated nuclear matrix. A minimum of about 40% of matrix-bound DNA synthesis continued from sites being used in vitro by isolated nuclei. Furthermore, nuclear matrices prepared from in vitro labeled nuclei were 5-fold enriched in DNA synthesized by the nuclei and were several-fold enriched, compared to total nuclear DNA, in a particularly high density labeled population of DNA molecules.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4016121     DOI: 10.1016/0167-4781(85)90020-x

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  3 in total

1.  Ultrastructural and biochemical comparisons of nuclear matrices prepared by high salt or LIS extraction.

Authors:  H C Smith; R L Ochs; D Lin; A C Chinault
Journal:  Mol Cell Biochem       Date:  1987-09       Impact factor: 3.396

2.  Mapping replicational sites in the eucaryotic cell nucleus.

Authors:  H Nakayasu; R Berezney
Journal:  J Cell Biol       Date:  1989-01       Impact factor: 10.539

Review 3.  The structure of the nucleus in normal and neoplastic prostate cells: untangling the role of type 2 DNA topoisomerases.

Authors:  William G Nelson; Michael C Haffner; Srinivasan Yegnasubramanian
Journal:  Am J Clin Exp Urol       Date:  2018-04-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.